Volta, Francesco
La Monica, Silvia
Leonetti, Alessandro
Gnetti, Letizia
Bonelli, Mara
Cavazzoni, Andrea
Fumarola, Claudia
Galetti, Maricla
Eltayeb, Kamal
Minari, Roberta
Petronini, Pier Giorgio
Tiseo, Marcello
Alfieri, Roberta
Funding for this research was provided by:
AstraZeneca
Università degli Studi di Parma (FIL-Quota incentivante)
Associazione Italiana per la Ricerca sul Cancro (IG2017-20074)
Università degli Studi di Parma
Article History
Accepted: 26 September 2023
First Online: 19 October 2023
Declarations
:
: Open access funding provided by Università degli Studi di Parma within the CRUI-CARE Agreement. This work was supported by the Italian Association for Cancer Research, Milan (grant IG2017-20074 PI M. Tiseo), by AstraZeneca, Milan Italy, and by the program “FIL-Quota Incentivante” of the University of Parma and co-sponsored by Fondazione Cariparma. The funders had no role in the study design, data collection and analysis, decision to publish, or manuscript preparation.
: The study was approved by the institutional review board of University-Hospital of Parma (Protocol 14033, 09/04/2018) and informed consent was obtained from all individual participants included in the study. All procedures performed in studies involving human participants were in accordance with the Helsinki declaration as revised in 2013 and its later amendments.
: FV, SLM, AL, LG, MB, AC, CF, MG, KE, RM, PGP, MT, and RA have no conflicts of interest that are directly relevant to the content of this article. MT received speaker and consultant fees from AstraZeneca, Pfizer, Eli-Lilly, BMS, Novartis, Roche, MSD, Boehringer Ingelheim, Otsuka, Takeda, and Pierre Fabre. MT has received institutional research grants from AstraZeneca and Boehringer Ingelheim. RA has received institutional research grants from AstraZeneca.
: Not applicable.
: All data generated or analyzed during this study are included in the article.
: Not applicable.
: Conceptualization: FV, SLM, PGP, MT, RA; data curation: MB, MG, CF; formal analysis: AC, AL, RM; funding acquisition: MT, RA; investigation: FV, SLM, LG, KE; supervision: PGP, RA, MT; writing, original draft: FV, SLM; writing, review and editing: PGP, MT, RA.